American Society of Gene + Cell Therapy
@asgct.bsky.social
Advancing knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease.
📢 Registration for the ASGCT 2026 Annual Meeting is officially open! Secure your spot to join thousands of cell and gene therapy experts in Boston, May 11-15, 2026. Register today: https://annualmeeting.asgct.org/register-attend/rates-registration
December 3, 2025 at 7:18 PM
📢 Registration for the ASGCT 2026 Annual Meeting is officially open! Secure your spot to join thousands of cell and gene therapy experts in Boston, May 11-15, 2026. Register today: https://annualmeeting.asgct.org/register-attend/rates-registration
We're thrilled to share just a few of the incredible speakers joining our FREE Empowering Patients Summit, held virtually March 12+13. You'll hear from these CGT leaders (and many more!): asgct.org/empowering
December 1, 2025 at 5:10 PM
We're thrilled to share just a few of the incredible speakers joining our FREE Empowering Patients Summit, held virtually March 12+13. You'll hear from these CGT leaders (and many more!): asgct.org/empowering
Join us this Thursday for a FREE webinar exploring the evolution of aptamers, from their initial discovery to their current role as precise, versatile tools surpassing antibodies in diagnostic and therapeutic applications. Register: https://bit.ly/3XLi7Np
Molecular Therapy Presents: Innovations in Aptamer Technology
Thursday, December 4 at 1 p.m. CT
www.asgct.org
December 1, 2025 at 3:05 PM
Join us this Thursday for a FREE webinar exploring the evolution of aptamers, from their initial discovery to their current role as precise, versatile tools surpassing antibodies in diagnostic and therapeutic applications. Register: https://bit.ly/3XLi7Np
FDA approves Itvisma, expanding access to gene therapy for spinal muscular atrophy. The one-time intrathecal treatment is approved for patients two years and older – the first gene replacement therapy available for this broader SMA population. Read more: https://bit.ly/3Kn9mpM
FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy
FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy
www.fda.gov
November 28, 2025 at 7:30 PM
FDA approves Itvisma, expanding access to gene therapy for spinal muscular atrophy. The one-time intrathecal treatment is approved for patients two years and older – the first gene replacement therapy available for this broader SMA population. Read more: https://bit.ly/3Kn9mpM
ASGCT is pleased to see two CGT products recognized with the Commissioner’s National Priority Voucher (CNVP). We continue to advocate for safe and effective regulatory frameworks. Read a summary of our recent comment letters on other FDA initiatives: https://bit.ly/43Tm5qP
ASGCT Comments on Key FDA Initiatives Supporting Cell and Gene…
ASGCT recently submitted three comment letters to the US Food and Drug Administration (FDA) focused on advancing regulatory flexibility and modernization…
www.asgct.org
November 26, 2025 at 4:38 PM
ASGCT is pleased to see two CGT products recognized with the Commissioner’s National Priority Voucher (CNVP). We continue to advocate for safe and effective regulatory frameworks. Read a summary of our recent comment letters on other FDA initiatives: https://bit.ly/43Tm5qP
Last week, the FDA approved Plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). This RNAi therapy represents a new treatment option for patients with FCS, a severe and rare genetic disease. Read more: https://bit.ly/47XTSlc
FDA approves drug to reduce triglycerides in adults with familial chyl
FDA approves drug to reduce triglycerides in adults with familial chylomicronemia syndrome
www.fda.gov
November 25, 2025 at 2:45 PM
Last week, the FDA approved Plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). This RNAi therapy represents a new treatment option for patients with FCS, a severe and rare genetic disease. Read more: https://bit.ly/47XTSlc
Master CGT fundamentals in our new FREE online course! Learn the essentials – from CRISPR to clinical trial design and more – on your own schedule. Visit the ASGCT Learning Center to enroll today: https://bit.ly/44bFKCj
November 24, 2025 at 6:43 PM
Master CGT fundamentals in our new FREE online course! Learn the essentials – from CRISPR to clinical trial design and more – on your own schedule. Visit the ASGCT Learning Center to enroll today: https://bit.ly/44bFKCj
FDA announces first nine recipients of Commissioner's National Priority Voucher program – including DB-OTO, a gene therapy for genetic hearing loss! The program aims to cut review times from 10-12 months to 1-2 months. More in The Advocate: https://bit.ly/4pr8Bek #ASGCTadvocacy
The Advocate: November 2025
Senate HELP Committee highlights CGT breakthroughs like sickle cell treatments as examples of U.S. biotech leadership – while raising concerns about…
bit.ly
November 21, 2025 at 3:05 PM
FDA announces first nine recipients of Commissioner's National Priority Voucher program – including DB-OTO, a gene therapy for genetic hearing loss! The program aims to cut review times from 10-12 months to 1-2 months. More in The Advocate: https://bit.ly/4pr8Bek #ASGCTadvocacy
Thanks to all who kicked off Breakthroughs in Targeted In Vivo Gene Editing with us today – what an incredible day of cutting-edge science and insights in this exciting field!
November 21, 2025 at 2:20 AM
Thanks to all who kicked off Breakthroughs in Targeted In Vivo Gene Editing with us today – what an incredible day of cutting-edge science and insights in this exciting field!
As cell and gene therapies revolutionize modern medicine, South America is emerging as a dynamic player on the global stage. Join this FREE webinar exploring South American technological frontiers: https://bit.ly/489b0mT
Around the World: Technological Frontiers in South American Gene and…
As gene and cell therapies revolutionize modern medicine, South America is emerging as a dynamic player on the global stage—leveraging scientific…
bit.ly
November 20, 2025 at 3:15 PM
As cell and gene therapies revolutionize modern medicine, South America is emerging as a dynamic player on the global stage. Join this FREE webinar exploring South American technological frontiers: https://bit.ly/489b0mT
"Our moment is now. It's now that we have the very first tools to start asking, what happens if we deliver gene therapy to the whole brain? Can we get this done?"
Watch our latest Community Quick Take with Dr. Sonia Vallabh on gene editing for prion disease: https://bit.ly/3X4YPCp
Watch our latest Community Quick Take with Dr. Sonia Vallabh on gene editing for prion disease: https://bit.ly/3X4YPCp
November 19, 2025 at 9:25 PM
"Our moment is now. It's now that we have the very first tools to start asking, what happens if we deliver gene therapy to the whole brain? Can we get this done?"
Watch our latest Community Quick Take with Dr. Sonia Vallabh on gene editing for prion disease: https://bit.ly/3X4YPCp
Watch our latest Community Quick Take with Dr. Sonia Vallabh on gene editing for prion disease: https://bit.ly/3X4YPCp
Secure your livestream access and unlock one year of on-demand recordings! 🔓 Don't miss out on this must-attend gene editing event: asgct.org/breakthroughs
November 19, 2025 at 6:40 PM
Secure your livestream access and unlock one year of on-demand recordings! 🔓 Don't miss out on this must-attend gene editing event: asgct.org/breakthroughs
Recent news reports highlighting commercial efforts to normalize heritable human genome editing (HHGE) underscore the urgent need for sustained vigilance, ethical clarity, and enforceable global governance. Read more: https://bit.ly/4r8iIGt
Global Scientific Consortium Reaffirms Position on Human Heritable…
Recent news reports highlighting commercial efforts to normalize heritable human genome editing (HHGE) underscore the urgent need for sustained vigilance,…
www.asgct.org
November 18, 2025 at 10:52 PM
Recent news reports highlighting commercial efforts to normalize heritable human genome editing (HHGE) underscore the urgent need for sustained vigilance, ethical clarity, and enforceable global governance. Read more: https://bit.ly/4r8iIGt
Can't travel to San Diego? Join our targeted gene editing event via livestream and get one year of on-demand access! 📱 Register: asgct.org/breakthroughs
November 17, 2025 at 5:05 PM
Can't travel to San Diego? Join our targeted gene editing event via livestream and get one year of on-demand access! 📱 Register: asgct.org/breakthroughs
We’d love to see you next week at Breakthroughs in Targeted In Vivo Gene Editing – in San Diego or online! You’ll hear new research from CGT leaders, including these featured speakers and many more: asgct.org/breakthroughs
November 13, 2025 at 4:07 PM
We’d love to see you next week at Breakthroughs in Targeted In Vivo Gene Editing – in San Diego or online! You’ll hear new research from CGT leaders, including these featured speakers and many more: asgct.org/breakthroughs
Check out the Q3 Landscape Report for the latest in the therapeutics pipeline, clinical targets, developer progress, and more! 🧬 Read the full report: https://www.asgct.org/news-publications/landscape-report
November 12, 2025 at 7:06 PM
Check out the Q3 Landscape Report for the latest in the therapeutics pipeline, clinical targets, developer progress, and more! 🧬 Read the full report: https://www.asgct.org/news-publications/landscape-report
The latest episode of the Molecular Therapy podcast is out now! This in-depth conversation focuses on an article recently published in @moltherapy.bsky.social titled “Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector.”
🎙️Listen: https://bit.ly/43o18UG
🎙️Listen: https://bit.ly/43o18UG
Generating CAR T cells in vivo with lentiviral vectors with… | ASGCT
Editor-in-Chief of Molecular Therapy, Dr. Joseph Glorioso, is joined by Rachael Nimmo, PhD, and Kyriacos Mitrophanous, PhD, to discuss “Efficient in vivo…
bit.ly
November 11, 2025 at 8:16 PM
The latest episode of the Molecular Therapy podcast is out now! This in-depth conversation focuses on an article recently published in @moltherapy.bsky.social titled “Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector.”
🎙️Listen: https://bit.ly/43o18UG
🎙️Listen: https://bit.ly/43o18UG
The #ASGCT2026 abstract submission window is officially OPEN! Present your research live in Boston, get published in @moltherapy.bsky.social, and network with global cell & gene therapy experts. Don’t miss this opportunity: https://bit.ly/3LVBtg0
Submission Information
Lean how and when to submit your abstracts, how abstracts are reviewed and selected, and how you'll be notified if your abstract is accepted.
annualmeeting.asgct.org
November 11, 2025 at 4:50 PM
The #ASGCT2026 abstract submission window is officially OPEN! Present your research live in Boston, get published in @moltherapy.bsky.social, and network with global cell & gene therapy experts. Don’t miss this opportunity: https://bit.ly/3LVBtg0
The Empowering Patients Summit is back! 🎉 Join us March 11 + 12 for this free virtual event to gain the latest insights and be inspired by powerful stories from the patient community. https://bit.ly/4hGwXOh
Empowering Patients 2026: A Cell and Gene Therapies Summit
This free, virtual Summit will bring together patients, caregivers, advocates, researchers, and industry leaders for two dynamic half-days of learning the…
www.asgct.org
November 7, 2025 at 7:45 PM
The Empowering Patients Summit is back! 🎉 Join us March 11 + 12 for this free virtual event to gain the latest insights and be inspired by powerful stories from the patient community. https://bit.ly/4hGwXOh
📢 AVAILABLE NOW: Breakthroughs in Targeted In Vivo Gene Editing abstracts!
View and download the collection of original research on our website, and don't miss your chance to dive deeper Nov. 20-21 in San Diego and virtually. https://bit.ly/47R1ndv
View and download the collection of original research on our website, and don't miss your chance to dive deeper Nov. 20-21 in San Diego and virtually. https://bit.ly/47R1ndv
Breakthroughs in Targeted In Vivo Gene Editing
Dedicated to cutting-edge solutions for targeted delivery, this event is your chance to engage with pioneering research, overcome tissue-specific…
www.asgct.org
November 3, 2025 at 11:15 PM
📢 AVAILABLE NOW: Breakthroughs in Targeted In Vivo Gene Editing abstracts!
View and download the collection of original research on our website, and don't miss your chance to dive deeper Nov. 20-21 in San Diego and virtually. https://bit.ly/47R1ndv
View and download the collection of original research on our website, and don't miss your chance to dive deeper Nov. 20-21 in San Diego and virtually. https://bit.ly/47R1ndv
October is #HealthLiteracyMonth! 🧠 Simple, trusted info on cell and gene therapies is just a click away: patienteducation.asgct.org
October 31, 2025 at 7:00 PM
October is #HealthLiteracyMonth! 🧠 Simple, trusted info on cell and gene therapies is just a click away: patienteducation.asgct.org
Sending a heartfelt thank you to @nordrare.bsky.social for hosting us at last week’s inspiring Rare Diseases and Orphan Products Breakthrough Summit! 🦓💙 We were grateful for the opportunity to celebrate the success stories that remind us what’s possible when innovation meets hope.
October 29, 2025 at 4:45 PM
Sending a heartfelt thank you to @nordrare.bsky.social for hosting us at last week’s inspiring Rare Diseases and Orphan Products Breakthrough Summit! 🦓💙 We were grateful for the opportunity to celebrate the success stories that remind us what’s possible when innovation meets hope.
The October edition of The Patient Press is here! Save the date for the 2026 Empowering Patients Summit, watch a clip of our Patient Education resources on @goodmorningamerica.bsky.social, and more: https://bit.ly/3Jl866c
The Patient Press: October 2025
Explore new membership categories for patient advocates, patients, and caregivers; save the date for the Empowering Patients Summit in March 2026; watch a…
patienteducation.asgct.org
October 28, 2025 at 8:05 PM
The October edition of The Patient Press is here! Save the date for the 2026 Empowering Patients Summit, watch a clip of our Patient Education resources on @goodmorningamerica.bsky.social, and more: https://bit.ly/3Jl866c
Big news! We’ve relaunched our ASGCT websites with a fresh look and enhanced functionality to make accessing critical CGT resources easier than ever.
🌐 asgct.org
🗓️ annualmeeting.asgct.org
💙 patienteducation.asgct.org
🌐 asgct.org
🗓️ annualmeeting.asgct.org
💙 patienteducation.asgct.org
October 28, 2025 at 12:15 AM
Big news! We’ve relaunched our ASGCT websites with a fresh look and enhanced functionality to make accessing critical CGT resources easier than ever.
🌐 asgct.org
🗓️ annualmeeting.asgct.org
💙 patienteducation.asgct.org
🌐 asgct.org
🗓️ annualmeeting.asgct.org
💙 patienteducation.asgct.org
ICYMI: Leaders from across the #CGT ecosystem gathered in Washington, DC last month for ASGCT’s 2025 Policy Summit, a forum that brought regulators, patient advocates, industry, + others together to discuss challenges + opportunities shaping the field. https://bit.ly/43vpSdy
Reflections from ASGCT’s 2025 Policy Summit
Leaders from across the cell and gene therapy (CGT) ecosystem gathered in Washington, DC, for ASGCT’s 2025 Policy Summit: a forum that brought regulators,…
bit.ly
October 22, 2025 at 6:36 PM
ICYMI: Leaders from across the #CGT ecosystem gathered in Washington, DC last month for ASGCT’s 2025 Policy Summit, a forum that brought regulators, patient advocates, industry, + others together to discuss challenges + opportunities shaping the field. https://bit.ly/43vpSdy